Affiliation: Food and Drug Administration
- Gender differences in the treatment of non-ST-segment elevation myocardial infarctionDale Tavris
Food and Drug Administration, Center for Devices and Radiological Health, Division of Epidemiology, USA
Clin Cardiol 33:99-103. 2010..One explanation may be that they tend to be treated less aggressively than men even when more aggressive treatment is warranted. The purpose of this analysis was to assess this issue...
- Long-term outcomes after transmyocardial revascularizationDale R Tavris
US Food and Drug Administration, Center for Devices and Radiological Health, Division of Epidemiology, Silver Spring, Maryland Electronic address
Ann Thorac Surg 94:1500-8. 2012....
- Bleeding and vascular complications at the femoral access site following percutaneous coronary intervention (PCI): an evaluation of hemostasis strategiesDale R Tavris
US Food and Drug Administration FDA, Silver Spring, MD, USA
J Invasive Cardiol 24:328-34. 2012..Since that time, several more VCDs have been approved by the Food and Drug Administration (FDA). This research evaluates the safety profiles of current frequently used VCDs and other hemostasis strategies...